Advertisement

Advertisement
Solid Tumors
Issues in Oncology

Low-Value Cancer Screenings May Continue for Years Following Guideline Change to Limit Unnecessary Tests

Stopping the widespread use of unnecessary, potentially harmful cancer screenings may take up to 13 years and potentially longer following the implementation of new guidelines, according to a recent study published by LeLaurin et al in BMJ Quality & Safety.

 

Gynecologic Cancers

Self-Collection Kit Mailings May Increase Cervical Cancer Screening Rates in Underserved Settings

Mail-in self-collection kits for human papillomavirus (HPV) were found to be effective at increasing cervical cancer screening rates compared with standard telephone reminders alone in a safety-net health-care setting, according to results from the PRESTIS trial published in JAMA Internal Medicine.  

 

Prostate Cancer

Localized Prostate Cancer: Long-Term Follow-up of Hypofractionated, Dose-Escalated vs Conventionally Fractionated RT

In a long-term follow-up of the phase III MD Anderson dose-escalated, hypofractionated prostate radiation study reported in the Journal of Clinical Oncology, Hassanzadeh et al compared hypofractionated intensity-modulated radiation therapy (HIMRT) vs conventionally fractionated intensity-modulated radiation therapy (CIMRT) in patients with predominantly low- or intermediate-risk localized prostate cancer.


Advertisement
Skin Cancer

Inherited Genetic Differences May Predict Resistance to Immunotherapy in Metastatic Melanoma

Researchers may have uncovered genetic differences that may help predict response to immune checkpoint inhibitors among patients with metastatic melanoma, according to a recent study published by Monson et al in Nature Medicine.

 

Issues in Oncology

ACS CAN Statement on Federal Cuts to Cancer Research

On May 30, President Donald Trump released his final proposed budget for Fiscal Year 2026, which contains $4.531 billion for the National Cancer Institute (NCI). This represents a cut of almost $2.7 billion, or approximately 37.2%, from the current fiscal year. 

Advertisement
Advertisement




More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Solid Tumors

Early-Onset Breast, Colorectal, Melanoma, Thyroid, Testicular, and Other Cancers Are on the Rise in the United States

A study by researchers at the National Cancer Institute (NCI) investigating cancer incidence in the United States between 2010 and 2019 has found that breast, colorectal, endometrial, pancreatic, and kidney cancers are becoming more common among individuals younger than age 50. Although the study...

Advertisement

FDA Approves Mitomycin Intravesical Solution for Recurrent Low-Grade Intermediate-Risk Non–Muscle-Invasive Bladder Cancer

On June 12, 2025, the U.S. Food and Drug Administration (FDA) approved mitomycin intravesical solution (Zusduri) for adult patients with recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer. Mitomycin intravesical solution is a reverse thermal hydrogel formulation of mitomycin...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Gynecologic Cancers

I Was an N-of-1 in a CAR T-Cell Therapy Trial for Ovarian Cancer

More than a decade after I was diagnosed with late-stage ovarian cancer, a phase I clinical trial at Moffitt Cancer Center and Research Institute in Tampa, Florida, investigating a dose of a novel follicle-stimulating hormone receptor (FSHR)-targeting chimeric antigen receptor (CAR) T-cell therapy...

Issues in Oncology

Cutting Cancer Research Funding Is A Costly Gamble With Millions of Lives

Richard J. Boxer, MD “The [National Cancer Institute (NCI)] is a national treasure. If funding is diminished, it will be catastrophic to millions of patients and families who will experience the devastation of cancer in the coming years,” Richard J. Boxer, MD, wrote in an editorial Viewpoint...

CancerCare Survey Reveals How Insurance Red Tape Impacts Cancer Treatment Delays

Findings from a first-of-its-kind national survey are included in “The Health Insurance Maze: How Cancer Patients Get Lost in the Red Tape of Utilization Management,” a new report from CancerCare which details the impact that prior authorization requirement and coverage stoppages have on patients...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Prostate Cancer

AACR Statement on Former President Joseph Biden’s Cancer Diagnosis

The American Association for Cancer Research (AACR) has issued the following statement regarding former President Joseph R. Biden’s prostate cancer diagnosis: “The American Association for Cancer Research (AACR) offers heartfelt support and well wishes to former President Biden and his family ...

Advertisement

Cell-Free DNA Fragmentomics–Based Model for Early Detection of Pancreatic Cancer

In a Chinese study reported in the Journal of Clinical Oncology, Yin et al attempted to develop a cell-free DNA (cfDNA) fragmentomics–based model for early detection of pancreatic ductal adenocarcinoma.   Study Details The study consisted of training and validation cohorts from several Chinese...

ASCO Post X Feed
Social Media Hub by Everwall